• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal

    2021-11-11 13:37:52XiaofenHuangYikeLiMeifengNieMingxiYueYufangLiZhijieLinHuirongPanMujinFangTingWuShaoweiLiJunZhangNingshaoXiaQinjianZhao
    Journal of Pharmaceutical Analysis 2021年5期

    Xiaofen Huang ,Yike Li ,Meifeng Nie ,Mingxi Yue ,Yufang Li ,Zhijie Lin ,Huirong Pan , Mujin Fang , Ting Wu , Shaowei Li ,c, Jun Zhang ,Ningshao Xia ,c,**, Qinjian Zhao ,*

    a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China

    b School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China

    c School of Life Science, Xiamen University, Xiamen, Fujian, 361102, China

    d Xiamen Innovax Biotech Company, Xiamen, Fujian, 361005, China

    Keywords:Thiol-modifying agent Monoclonal antibody Antigenicity loss Epitope-specific Conformational stability

    ABSTRACT Thimerosal has been widely used as a preservative in drug and vaccine products for decades. Due to the strong propensity to modify thiols in proteins,conformational changes could occur due to covalent bond formation between ethylmercury (a degradant of thimerosal) and thiols. Such a conformational change could lead to partial or even complete loss of desirable protein function. This study aims to investigate the effects of thimerosal on the capsid stability and antigenicity of recombinant human papillomavirus(HPV) 18 virus-like particles (VLPs). Dramatic destabilization of the recombinant viral capsid upon thimerosal treatment was observed. Such a negative effect on the thermal stability of VLPs preserved with thimerosal was shown to be dependent on the thimerosal concentration. Two highly neutralizing antibodies,13H12 and 3C3,were found to be the most sensitive to thimerosal treatment. The kinetics of antigenicity loss, when monitored with 13H12 or 3C3 as probes, yielded two distinctly different sets of kinetic parameters, while the data from both monoclonal antibodies (mAbs) followed a biphasic exponential decay model. The potential effect of thimerosal on protein function, particularly for thiolcontaining proteinaceous active components, needs to be comprehensively characterized during formulation development when a preservative is necessary.

    1. Introduction

    Thimerosal, due to its bacteriostatic and fungistatic properties,has been widely used as a preservative in formulations for biologics and drug products [1-3]. In the late 1990s, concerns were raised about whether thiomersal-containing vaccines might contribute to the development of autism and other neurodevelopmental disorders in children. However, no definitive evidence from reputable scientific studies was available to support these claims [4-7]. The WHO Consultation (April 3-4, 2012) reaffirmed the view that the benefits of using thiomersal-containing multi-dose vaccines far outweighed any risks [8]. Currently, thimerosal is still in use in several licensed vaccines, including meningococcal and multipledose seasonal influenza vaccines (Table S1), and other biological products [3].

    Having been widely used for decades as a vaccine preservative,thimerosal had been thought to be inert with respect to vaccine potency until the last 10-20 years [9]. An earlier study by Sawyer et al. [10] showed that thimerosal had deleterious effects on the potency of inactivated poliovirus vaccine (IPV) as measured by monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA), but the overall potency did not change when using a polyclonal antibody preparation.The ELISA potency based on mAbs of all three poliovirus antigens in the presence of thimerosal showed a decrease to different degrees for the different types over the observation period [10]. These studies provided the first report on the epitope-specific loss of antigenicity of a vaccine product in the presence of thimerosal. In addition, Kraan et al. [11] found that thimerosal negatively affected the antigenicity of lyophilized inactivated poliovirus vaccine by ELISA using a mixture of serotypespecific anti-poliovirus mAbs. These results showed that vaccine preservatives might result in the partial or even complete loss of antigenicity of vaccine antigens when monitored with specific mAbs.While the negative impacts on vaccine antigenicity and immunogenicity were observed, the time course of such an alteration has been poorly understood in the vaccine formulations.

    The presence of the correct conformation of protein antigens is the structural basis for vaccines to elicit functional antibodies and to confer immunity against infectious diseases.Thus,thimerosal as a preservative in vaccine formulations should be compatible with the antigens for maintaining the virion-like epitopes. Human papillomaviruses(HPVs),especially HPV16 and HPV18,are the two most common high-risk HPV types that cause cervical cancer[12].Currently, several HPV prophylactic vaccines based on virus-like particles (VLPs) have been licensed against HPV infection [13]. It has been reported that the ELISA titres in human sera of HPV VLPbased vaccine(types 16/18)preparations showed an increase upon immunization. However, the thimerosal-containing vaccine failed to induce neutralizing antibody responses [14]. In our previous study,using a mouse model,the immunogenicity of the HPV16 and HPV18 VLPs antigens in the formulation was shown to be significantly decreased in the presence of thimerosal [15].

    In this study, a panel of murine mAbs against HPV18 VLPs was assessed for its sensitivity with respect to thimerosal treatment.Two representative mAbs with the highest sensitivity to thimerosal treatment, 13H12 and 3C3, were chosen to perform the in-depth characterization of the epitope alteration with respect to the time scale of antigenicity loss and thimerosal concentration dependence.The kinetics analyses of HPV18 VLP antigenicity loss yielded unique information on the kinetic properties for the changes in immunoreactivity to these two mAbs. In addition, the decrease in binding activity to different mAbs of HPV18 VLP antigens adsorbed on aluminium-based particulate adjuvants in the presence of thimerosal was visualized using fluorescence imaging-based high content analysis.

    2. Materials and methods

    2.1. Recombinant HPV18 VLPs

    The recombinant HPV18 L1 protein was expressed inEscherichia colifrom Xiamen Innovax Biotech (Xiamen, China). The recombinant HPV18 VLPs were produced and purified according to the previously published procedures [16].The concentration of HPV18 L1 protein was measured using a bicinchoninic acid (BCA) assay(Thermo Fisher Scientific, Waltham, MA, USA) with bovine serum albumin as a standard.

    2.2. Monoclonal antibodies

    A total of 26 in-house anti-HPV18 VLPs mAbs were produced from hybridoma cell lines, provided by Xiamen Innovax Biotech and purified with a Protein A column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The concentration of the purified mAbs was determined by Ultrospec 2100 pro UV/Visible Spectrophotometer(GE Healthcare,Piscataway,NJ,USA)at 280 nm(OD 1.4 for a 1 mg/mL IgG solution). The purified 3C3 mAb was labelled with horseradish peroxidase (HRP) by a periodate conjugation method as previously reported [17].

    2.3. Human and mouse serum samples

    The serum samples derived from humans and mice for this study were reported previously [15,18]. Briefly, human serum samples (n=8) were collected from volunteers immunized with three doses of an investigational bivalent (HPV16/18) vaccine(Xiamen Innovax, Xiamen, China). Human serum samples 1-8 were numbered as 12,1,27,5,4,29,18,and 26 described by Zhang et al. [18]. Mouse serum samples (n=8) were collected from mice after 6 weeks of immunization with three doses of a thimerosalfree formulation of a pentavalent vaccine (HPV6/11/16/18/HEV).All sera-based studies were carried out in accordance with the guidelines of The Code of Ethics of the World Medical Association(Declaration of Helsinki) and approved by the Xiamen University Laboratory Animal Management Ethics Committee (XMULAC20160032) and Ethics Committee of Jiangsu Provincial Center for Disease Prevention and Control (JSJK2019-A006-02).

    2.4. Morphology and particle size of the VLPs

    Thimerosal(AR,≥98.0%,Lot No.F20110111)was purchased from Sinopharm Chemical Reagent Co.,Ltd.(Shanghai, China). A concentration of 0.01% (m/V) was the most commonly used concentration for thimerosal in vaccine formulations (Table S1). HPV18 VLPs(0.1 mg/mL) were treated with 0.01% (m/V) thimerosal for 24 h at 4°C and then treated with the same concentration of native HPV18 VLPs, applied to a carbon-coated grid and stained with 2% (m/V)uranyl acetate after removal of excess fluid.The morphologies of the HPV18 VLPs were examined using a JEM2100HC transmission electron microscope(JEOL,Tokyo,Japan)operated at 120 kV.

    Table 1 Conformational stability analysis of HPV18 VLPs upon thimerosal treatment detected by DSF. The Tm values were measured in three independent replicates.

    Table 2 Characteristics of a panel of HPV18 murine monoclonal antibodies and their relative binding activity to thimerosal treated VLPs (rEC50 = EC50 (thimerosal-treated)/EC50 (control))compared to the control.

    2.5. Thermal stability by differential scanning fluorimetry (DSF)and cloud point analysis

    DSF[19,20]was carried out by a real-time PCR instrument,Bio-Rad T100? Thermal Cycler (Hercules, California, USA). First,200 μg/mL HPV18 VLPs were treated with different concentrations(0%,0.001%,0.005%,0.01%,0.02%,and 0.05%(m/V))of thimerosal for 24 h at 4°C.The fluorescent dye,SYPRO Orange(Sigma-Aldrich,St.Louis,MO,USA),was diluted 50×from its stock concentration using deionized water and then mixed at a volume ratio of 1:9 of the antigens to thimerosal. Subsequently, 50 μL of the mixed solution was added to each well of the plate.Then,the PCR plate was sealed and centrifuged at 1000 rpm for 1 min.The real-time PCR machine was used to heat the samples at intervals of approximately 0.5°C ramping from 10°C to 90°C. Fluorescence emission was collected using a HEX filter (560 nm-580 nm). Melting curves of fluorescence intensity at 570 nm were obtained with a Bio-Rad CFX Manager. The transition midpoint temperature (Tm) values were determined by derivative analysis using the software package OriginPro 9.1 (Origin Lab Corp., Northampton, MA, USA). Each sample was determined by triplicate measurements. The cloud point with temperature ramping was determined by turbidity measurements with a UV2100PRO, which was equipped with an external Peltier thermal controller in the temperature range of 30-90°C. The samples were measured at a concentration of 0.1 mg/mL L1 protein. The optical density at 350 nm was used to detect the signals due to protein aggregation.

    Fig.1.Characterization of the morphology and thermal stability of HPV18 VLPs with or without thimerosal treatment. (A) The morphologies of the control and 0.01% (m/V)thimerosal-treated HPV18 VLPs.(B)The thermal stability of VLP antigens treated with different concentrations of thimerosal as monitored by DSF[19,20].Tm differences were across the range from 50.0 °C(0.05%(m/V)thimerosal-treated)to 75.5 °C(control).(C)The cloud point temperatures of thimerosal-treated and control VLPs were approximately 43 °C and 71 °C, respectively.

    2.6. Comparative study of polyclonal antibody binding activity to VLPs

    First,80 μg/mL HPV18 VLPs were pre-incubated in the presence of 0.01% (m/V) thimerosal for 24 h at 25°C. Then, the microplates were coated at 25°C for 2 h with 100 ng/well VLPs with or without thimerosal treatment. After plate blocking, the plates were incubated at 25°C for 1 h with 100 μL of 2-fold serial dilutions of human serum and 150 μL of 3-fold serial dilutions of mouse serum diluted with assay diluent.After 5 wash cycles,a goat-anti-mouse or goatanti-human IgG horseradish peroxidase (HRP) conjugated at 1:5000(V/V)was added to the plates and incubated for 1 h at 25°C.Subsequently,100 μL per well tetramethyl benzidine substrate solution (Beijing Wantai Biological Pharmaceutical Co., Ltd., Beijing,China) was added and incubated for 10 min at 25°C. The reaction was stopped by adding 50 μL of 2 M sulfuric acid per well,and the intensity in the well was measured at 450 nm against 630 nm as the background. The binding activity of the control or thimerosal treated VLPs was defined as the antibody dilution required to achieve 50% of the maximal signal (ED50). The relative ED50(ED50(control)/ED50(thimerosal-treated)) was used to measure the relative binding activity of the polyclonal antibody to HPV18 VLPs.

    2.7. The mAb binding activity to the VLPs with or without thimerosal treatment

    Direct binding ELISA was used to evaluate the median effective concentration (EC50) of mAbs in solution against the surfaceimmobilized recombinant HPV18 VLPs with or without thimerosal treatment.Some VLPs(80 μg/mL)were treated with 0.01%(m/V)thimerosal for 24 h at 4°C.Then,the microplates were coated at 25°C for 2 h with 100 ng/well VLPs with or without thimerosal treatment. After plate blocking, the plates were incubated and maintained at 25°C for 1 h with 100 μL of 2-fold serial dilutions(starting with 1 μg/mL mAbs) of 26 different mAbs using assay diluent. The binding activity of the control VLPs or thimerosaltreated VLPs was defined as the antibody concentration required to achieve 50% of the maximal signal (EC50, ng/mL). The relative EC50(EC50(thimerosal-treated)/EC50(control)) was used to measure the relative binding activity for mAbs to HPV18 VLPs coated on ELISA plates.

    2.8. Surface plasmon resonance (SPR) for antigenicity analysis

    The SPR technique was employed to assess the antigenicity of HPV18 VLPs using a Biacore 3000 instrument (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) with similar procedures as previously described[21].Briefly,80 μg/mL VLPs were pre-incubated in the presence of thimerosal at different concentrations(0%,0.001%,0.005%, 0.01%, and 0.02% (m/V)), diluted to 20 μg/mL and detected in-cycle for 24 h at 25°C. Two mAbs (3C3 and 13H12, 30 μg/mL)were captured by chemically immobilized GAM-Fc on the chip surface with HBS-EP running buffer (0.01 M HEPES, 0.5 M NaCl,3 mM EDTA, 0.005% (V/V) Tween-20, pH 7.4). The HPV18 VLPs treated with thimerosal subsequently flowed through the chip surface binding to the captured mAbs.The relative antigenicity was calculated by normalizing the rRU (RUAg/RUAb) of the thimerosaltreated VLPs in a flow cell(0%,0.001%,0.005%,0.01%,and 0.02%(m/V)) to that of the control HPV18 VLPs in a separate flow cell in the same assay cycle.

    2.9. Sandwich ELISA for VLP antigenicity analysis

    Sandwich ELISA was utilized to determine the antigenicity of the HPV18 VLPs with 0.01% (m/V) thimerosal treatment compared to the control for 24 h at 4°C. The 96-well micro-plate was coated with the mAb 13H12 as the capture antibody (100 ng per well) at 4°C overnight. After plate coating and blocking, a set of eleven serial two-fold dilutions of HPV18 VLPs with or without thimerosal treatment,starting at 4 μg/mL,were added and incubated at 25°C for 1 h. Then, 100 μL of mAb 3C3 labelled with HRP used as the detection antibody diluted 1:3000(V/V)in assay diluent was added and incubated at 25°C for 1 h.

    2.10. The antigenicity of VLP thimerosal containing vaccine detected by imaging-based high content analysis (HCA)

    Fig.2.The altered antigenicity of HPV18 VLPs to antibodies in human or mouse serum.Human and mouse serum samples were taken after post immunization using intact HPV18 VLPs based vaccines. (A) Human-7 and mouse-4 were the serum samples that showed the highest sensitivity to thimerosal treatment. The binding activities of eight different human and mouse serum samples to VLP antigens with and without thimerosal treatment are shown in Figs. S2 and S3. (B) Binding activity of eight different human and mouse serum samples to the control or thimerosal-treated VLPs (ED50) which is the serum dilution fold required to achieve 50% of the maximal signal. (C) The relative binding activity(rED50 = ED50 (control)/ED50 (thimerosal-treated)) of eight different human and mouse serum samples to thimerosal-treated VLPs.

    An Opera Phenix high content system (PerkinElmer, Wellesley,MA, USA) and fluorescence plate reader (Beckman Coulter, Inc.,Brea, CA, USA) were used for the antigenicity analysis of HPV18 antigens adsorbed on aluminium-based adjuvants. VLPs (160 μg/mL) were preincubated with 0.02% (m/V) thimerosal at 25°C for approximately 30 min, and then the adjuvant was added to the antigen solution at a volume ratio of 1:1 and mixed sufficiently.Then,the solution was kept at 4°C for 24 h before testing.The final concentration of thimerosal was 0.01%(m/V),and the concentration of Al was 420 μg/mL. Two murine mAbs, 13H12 and 3C3, were labelled by DyLight 488 Amine-Reactive Dye (Pierce/Thermo Scientific,Rockford,IL,USA)according to the instructions.These mAbs were used to detect the antigenicity of the VLP antigens in the fluorescence immunoassay.The antigenicity of antigens is based on the measurement of total fluorescence intensity of HCA or using a plate reader to measure the thimerosal-treated VLPs compared to the control.

    2.11. Statistical analysis

    EC50values of ELISA and HCA data were calculated using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). For kinetics studies, a double exponential equation was fitted to the Biacore data using the software package OriginPro 9.1.

    3. Results

    3.1. The morphology and thermal stability of VLPs in the presence of thimerosal

    The transmission electron microscope (TEM) images showed that the HPV18 VLPs with thimerosal treatment were morphologically similar to the control and did not show any observable VLP aggregates or significant deformation of the spherical particles(Fig. 1A). However, the thermal stability of the HPV18 VLPs upon thimerosal treatment was dramatically reduced as reflected by a lower transition temperature by DSF or a lower cloud point for thermally induced aggregate formation.Tmof the control group was 75.5°C, while theTmfor thimerosal-treated HPV18 VLPs decreased from 74.5°C to 50.2°C (Table 1, Figs. 1B and S1), a reduction of 25.3°C in the transition temperature (Table 1). The cloud point was defined as the temperature when the discrete VLPs began to agglomerate as monitored at a given wavelength by the light scattering signals due to larger particle formation. The cloud point temperatures of HPV18 VLPs with or without thimerosal treatment were approximately 43°C and 71°C, respectively(Fig.1C). The observed difference of 28°C indicated that the VLPs treated with thimerosal have a much stronger propensity to aggregate during heat stress,indicating dramatic destabilization of the recombinant viral capsid.

    3.2. Polyclonal antibody binding activity to VLPs with thimerosal treatment

    Fig.3.The amplitude of changes to coating antigens reflected upon thimerosal treatment.The binding ability of HPV18 VLPs with or without thimerosal treatment to the mAbs was measured by direct binding ELISA. (A) The binding profiles of three representative mAbs (13H12,14E9 and 11A3) to 0.01% (m/V) thimerosal-treated HPV18 VLPs compared to the control are shown.(B)The correlation between the binding affinity and the sensitivity to thimerosal treatment of VLPs for different mAbs.This figure was derived from Figs.S4A and B.

    HPV18 VLPs antigens as coating antigens, with or without thimerosal treatment,were used to measure the binding activity of the serum samples from animals or humans immunized with control VLPs.The activity of the polyclonal antibodies in the serum samples was shown to decrease to varying degrees upon treatment with the coating antigens(Figs.2A and B,S2 and S3).The amplitude of change was more pronounced for the mouse serum samples.When compared to the control coating antigen, the relative binding activity (rED50=ED50(control)/ED50(thimerosal-treated)) of the thimerosal-treated antigen on the plate showed an average 6-fold reduction in the mouse serum group and a 2.5-fold decrease in the human serum group (Fig. 2C). These results indicated that the epitopes in the recombinant HPV 18 capsid are somehow altered upon thimerosal treatment,lowering the binding of native antigenelicited antibodies when the assays were performed in parallel using two different coating antigens.

    3.3. The effects of thimerosal on VLP antigenicity

    3.3.1. Varying degrees of mAb sensitivity to thimerosal-treated HPV18 VLPs

    As shown in Table 2 [18,22] and Fig. S4A, the degree of sensitivity of a panel of 26 mAbs to thimerosal-treated HPV18 VLPs was ranked and categorized into four different groups according to the corresponding fold change in relative EC50(rEC50=EC50(thimerosal-treated)/EC50(control)) values. The majority of mAbs were shown to have decreased (Groups I and II in Table 2) or similar binding activity(Group III in Table 2)upon thimerosal treatment.In particular,upon thimerosal treatment, the binding activity of 13H12 and 3C3 to HPV18 VLPs showed a reduction of up to 20-to 30-fold.A small portion of the mAbs showed a slight increase in binding activity to thimerosal-treated VLP antigens(e.g.,11A3 in Fig.3A and Table 2).Not surprisingly,the sensitivity to thimerosal-treated VLPs showed no apparent correlation to their affinity to VLP antigens (Fig. S4B),as the thimerosal-treated changes may be unique for any given mAb due to the nature and uniqueness of the epitope it recognizes.13H12 and 3C3, the two VLPs highly sensitive to thimerosal treatment, are also elite virus neutralizers (NC50<10 ng/mL), top binders to the VLPs and highly conformation-dependent. This would suggest that the epitopes sensitive to thimerosal treatment are also likely to be clinically relevant epitopes. In contrast, 9F5, a high affinity antibody with no virus neutralization capacity, exhibited no sensitivity to thimerosal-treated VLPs(Fig. 3B).

    3.3.2. Thimerosal concentration dependence of the antigenicity reduction

    Fig.4.The ELISA binding activity of two mAbs(13H12 and 3C3)to VLP antigens after pretreatment with thimerosal.(A)The binding profiles of two mAbs(13H12 and 3C3)to VLP antigens treated with 0.01%(m/V)thimerosal at different time points.(B)rEC50 values at different processing time points treated with different thimerosal concentrations.(C)The antigenicity of VLPs was measured by two mAbs (capture: 13H12, detection: 3C3-HRP) using a sandwich ELISA.

    As presented in Figs.4A and B,the OD450curves clearly showed a time-dependence (up to 48 h tested) and thimerosal concentration dependence. However, the decreasing trends in antigen binding to two mAbs (3C3 and 13H12) appeared to be unique for each mAb (Fig. 4B). For 3C3, the plateauing effect appeared at higher thimerosal concentrations.These results indicated that mAb 13H12 was more sensitive than 3C3 to thimerosal treatment at intermediate thimerosal concentrations(i.e.,0.005%and 0.01%(m/V))(Fig.4B).In addition to the one-site binding assays,the relative antigenicity was also measured quantitatively by two mAb-based(capture: 13H12, detection: 3C3) sandwich ELISA assays. The EC50values showed a 12-fold increase from 83 ± 1.1 ng/mL to 992 ± 1.1 ng/mL, when the VLPs were treated with thimerosal,indicating substantial weakening of the VLPs binding to these mAbs(Fig. 4C).

    3.3.3. The kinetics of epitope-specific antigenicity loss

    The sensor chip based SPR method was used to study the kinetics of HPV18 VLPs antigenicity alteration upon thimerosal treatment. SPR binding signals can be monitored in real time without need for labelling of either of the binding partners.Fig.5A is a schematic diagram showing the detection principle of the SPR sensorgram using mAbs as molecular probes. The biphasic loss of antigenicity (normalized to the control at every time point) of the VLPs due to thimerosal treatment is compared to that of a control sample(left panel of Fig.5B).The data were then fitted reasonably well to a double exponential decay model in the right panel of Fig. 5B with the parameters from the fitting tabulated in Table S2.The loss of antigenicity of VLP antigens occurred in a thimerosal concentration dependent manner (Fig. 5C). The relative antigenicity of 3C3 and 13H12 to VLPs by 0.01%(m/V)thimerosal treatment was reduced by approximately 70%-80% in the first 24 h. The antigenicity loss by SPR was also agreeable with the data obtained from the direct binding ELISA where the VLPs, with or without thimerosal treatment,were coated on the plate(Fig.4B).As shown in Table S2, the majority of antigenicity loss occurred in the fast phase, with an Afast/(Afast+ Aslow) ratio of 0.65 or higher for mAb 13H12 in the middle-and high-dose groups(≥0.005%(m/V)),while the ratio was observed for 3C3 in the low-dose groups(≤0.005%(m/V)). Thekfastof the antigenicity loss of VLPs to 13H12 was approximately 5-50 times higher in the lowest-dose group(0.001%(m/V))than in the middle-or high-dose groups(≥0.005%(m/V)).For 3C3,thekfastin the lowest-dose group (0.08 ± 0.007 min-1) was only 3.0-3.5 times higher than that in the middle-or high-dose groups(Table S2).Thekfastvalues of both mAbs 13H12 and 3C3 were very close in the high-dose groups(≥0.01%(m/V)),which could indicate a large excess of ethylmercury, so the modification of the thiol (s)followed pseudo-first-order kinetics.

    Fig.5.The kinetics of HPV18 VLPs antigenicity loss as measured by SPR.(A)Schematic diagram showing the SPR measurement process.The binding activities of mAbs to the native and thimerosal-treated VLPs were measured at different times,and the binding cycles were repeated for 24 h.Each cycle for the binding activity yielded a data point.(B)In the left panel of Fig. 5B, the relative antigenicity of HPV18 VLPs with different concentrations of thimerosal treatment was measured by the mAbs 13H12 and 3C3. The kinetics of antigenicity loss upon thimerosal treatment was fitted to a double exponential equation,F(t)=Afast·exp(-kfast t)+Aslow·exp(-kslow t)+C,and is shown in the right panel of Fig.5B.In the inset, the first 4 h of the kinetics of antigenicity loss of VLPs is shown. (C) Dose-response relationship between the binding capacity and thimerosal concentration.

    3.4. Visualization of the thimerosal-induced reduction in VLP antigenicity

    As reported in the previous sections,the antigenicity in solution was measured by a one-site or two-site binding assay based on mAbs. Most vaccines are adjuvanted, containing the particleadsorbed antigens in the formulation. In this part, an in situ method (HCA) was developed for visualizing and evaluating the antigenicity of VLP antigens adsorbed on micrometre-scale aluminium-based adjuvants in the presence of thimerosal. The distribution of fluorescence signals from the labelled mAbs on adjuvant particles with the adsorbed VLP antigen was clearly observed. The binding activity of mAbs 13H12 and 3C3 to the thimerosal-treated VLP antigen adsorbed on the adjuvant was shown to decrease according to the changes in fluorescence intensity owing to the labelled mAbs(Fig.6A).The antigenicity of VLP antigens in the presence of thimerosal was expressed by the EC50values, which was approximately 7- and 5-fold higher than their control groups for these two mAbs tested(Fig.6B).The magnitude of change observed on the surface adsorbed antigen using these two mAbs separately was also in agreement with the antigenicity loss (approximately one order of magnitude) from the sandwich ELISA, where these two mAbs were used as capture (13H12) and detection (3C3) antibodies, respectively(Fig. 4C).

    4. Discussion

    In our previous studies, structural alterations were observed in HPV18 VLPs with thimerosal treatment via cryo-electron microscopy and three-dimensional reconstruction of the recombinant viral capsid. The reduction of immunogenicity of HPV16/18 due to thimerosal treatment was also demonstrated by the overall antibody or neutralizing antibody, as well as with epitope-specific competition. Covalent modifications of proteins by thimerosal may be the underlying mechanism for conformational changes that lead to reduced immunogenicity[15].Among the four types of HPV studied (6, 11, 16 and 18), HPV 16 and 18 (type 18 in particular)showed the most prominent effects on structure and function due to the presence of the commonly used preservative thimerosal[15].In the present study, we focused on capsid destabilization and antigenicity changes probed with a panel of murine mAbs of the recombinant HPV 18 viral capsid. Similarly, it has been reported that the epitope for a well-studied neutralizing mAb, mAb H16.V5 against HPV16 L1 VLP, was destroyed after incubation with thimerosal[14].Like H16.V5 for HPV16,both 13H12 and 3C3 used in this study, are highly neutralizing mAbs for HPV18. These observations warrant more cautions on thimerosal use for protein based vaccines.

    Therefore,the widely used vaccine preservative thimerosal may be not‘inert’with respect to the structure and function of the active protein components in drug or vaccine formulations. Recently,Strohmidel et al. [23] found the covalent binding between the EtHg+derived from thimerosal and haemagglutinin of a seasonal tetravalent influenza vaccine.The thiol-containing vaccine antigens are likely to be modified,as thimerosal is a specific thiol-capping or thiol-reactive agent. In this study, dramatic capsid destabilization of HPV18,probably due to thiol modification(s)at some accessible site(s),was demonstrated with the substantially reduced transition temperature in protein thermal unfolding by 25.3°C and by 28.7°C from the cloud point measurement with an enhanced propensity to aggregate upon thermal stress (Table 1 and Fig. 1C). In terms of function,a panel of mAbs showed varying degrees of alterations in binding activity to the HPV18 VLPs antigens upon thimerosal treatment.Specifically,the two mAbs(13H12 and 3C3)that showed the highest sensitivity to thimerosal treatment are also typespecific with high virus neutralizing efficiency. The kinetic differences in the antigenicity loss when monitored with these two distinctly different mAbs(13H12 and 3C3)would indicate that the loss of immunoreactivity is epitope-specific. Both the ELISA(measuring the immunocomplexes at a given equilibrium)and the SPR-based kinetic binding assay (measured in real time with no wash steps) yielded similar conclusions for the thimerosal concentration dependence and the epitope-specific manner of the antigenicity changes.

    Fig.6.Visualization of the VLP antigenicity decreases in the presence of thimerosal. (A) HCA images of the antigenicity of mAbs 13H12 and 3C3 to HPV18 VLPs adsorbed on aluminium adjuvants in the presence of thimerosal or absence of thimerosal.The intensity of fluorescence in only part of the whole visual field was read by the Opera Phenix high content system.(B)The antigenicity of VLP antigens with or without thimerosal treatment was analysed by a fluorescence plate reader.The EC50 means the concentration of antigen required to achieve 50% of the maximal signal.

    The phenomenon of epitope alterations in the presence of thimerosal has been reported for other vaccines. Kraan et al. [11]reported that the presence of thimerosal resulted in a temperaturedependent loss of polio D-antigen by D-antigen ELISA using a mixture of serotype-specific anti-poliovirus mAbs.D-antigen could be recovered by addition of L-cysteine into the thimerosalcontaining vaccine formulation, probably through the regeneration of some critical thiol group(s)by the incoming free thiols in the form of overwhelming amount of cysteine. Similarly, a significant reduction was observed in its immunoreactivity by using a specific mAb-based assay for a thimerosal-containing formulation of glycoprotein 63 fromLeishmaniaafter one year of storage at 4°C[24]. The findings presented by Harmsen et al. [25] showed that thimerosal could stimulate intact (146S) foot-and-mouth disease virions to dissociate into 12S particles when monitored with mAbbased ELISA. Such dissociation could result in strongly reduced immunogenicity.

    Although alterations in the antigenicity and immunogenicity of vaccine antigens had been observed,the in-depth characterization of the kinetics of the thiol modification of antigens was not previously available. The kinetics of epitope modification could vary because the reactivity and accessibility of the thiol groups could differ significantly. It has been reported that the antigenicity of poliovirus type 2 was unchanged when ELISA was performed with monoclonal 9Ab after thimerosal incubation for 1 h at 25°C.However, the other mAb (monoclonal 7Ab) based potency of poliovirus type 2 was completely lost within 5 min of incubation with thimerosal at 25°C or 37°C [10]. In this study, the SPR data showed that the half-life of the relative antigenicity loss for either 13H12 or 3C3 was approximately 6 or 9 h based on thekslowat 25°C upon thimerosal treatment. If the HPV vaccine formulation contained 40 μg of HPV18 L1 proteins in a 0.5 mL dose containing 0.01%thimerosal,the mole ratio of Hg+from thimerosal to cysteines(14)in the HPV18 L1 proteins was 11(0.125 μmol:0.0112 μmol).If only one cysteine is accessible for forming a covalent bond with an incoming EtHg+,the molar ratio would be 150.The presence of an overwhelming excess of ethylmercury compared to the target thiol group(s) also explained the good fits using the biphasic pseudofirst-order kinetics model for the antigenicity loss data obtained after monitoring with two mAbs(Fig.5B and Table S2).In addition,it has been reported that the mercury(II) tightly bonds to the histidine imidazole tightly and thekfast(13.28 ± 0.07 min-1) is approximately one or two orders of magnitude higher than thekfastfrom SPR data (0.02-1.2 min-1) [26]. The kinetics results of antigenicity loss should rule out the binding to the imidazole of histidine residues to be the basis for immunoreactivity change, as this would be a much faster event.Thiol modification is likely to be the underlying chemical events, causing impairments in clinically relevant epitopes.

    Thimerosal can spontaneously degrade into thiosalicylic acid and ethylmercury in aqueous media.The strong affinity of mercuric ions (Hg2+) and their alkyl derivatives towards sulfhydryl groups(-SH) in amino acids, peptides and proteins is well documented[27-29].An in vivo study in humans performed by Trümpler et al.[30]reported the observation of ethylmercury-glutathione adducts.They also investigated the interaction between β-lactoglobulin A and thimerosal in simulated physiological conditions (pH 7.4, at 37°C) for 1 h, and the results showed that a free thiol residue in peptide T13 (amino acids 104-124) is the binding site of ethylmercury by means of LC/ESI-TOF-MS and LC/ICP-MS[31].Hogeback et al.[32]studied the adduct formation of organic mercury species with carbonic anhydrase and heamoglobin,and found that the free cysteine residues within proteins are the binding sites of methylmercury and ethylmercury cations. Janzen et al. [33] also showed that the binding stoichiometry correlates with the number of free thiols in the α- and β-chains of heamoglobin. In addition, thimerosal forms a bovine serum albumin-ethylmercury adduct with thiosalicylic acid release through the free Cys 34 residue and changes the conformation of bovine serum albumin[34].In another study, Ishii et al. [35] found that HPV16 pseudovirions lose their infectivity to HeLa cells after incubation with thiol-reactive reagents.It has been demonstrated that HPV16 L1 protein-free thiols in C146, C225 and C229 are accessible to thiol reactive agents by mass spectrometry and mutational analysis. The capping of these thiols or ethylmercury-cysteine adduct formation might result in reduced infectivity[35].Since sulfhydryl modifications via covalent bonding should be responsible for the epitope alteration of the HPV18 viral capsid, further efforts are needed to identify the specific cysteine residue(s)involved in the thiol modification of HPV18 VLPs antigens in the presence of thimerosal.

    Currently, although thimerosal-free single-dose vials and peadiatric vaccines are required,a preservative is still necessary in multi-dose vials of influenza vaccines (Table S1). Therefore,choosing thimerosal as a preservative for future use needs to be carefully studied based on its molecular structure, especially for thiol-containing proteins in vaccines and other biological products.In-depth characterization should be performed on the potential impact to the antigen structures and, even more importantly, its functions such as antigenicity and immunogenicity. Recently,Agarwal et al. [36] found that thimerosal destabilizes aluminiumbased adjuvant adsorbed recombinant subunit rotavirus vaccine antigens and induces loss in immunoreactivity as reflected by mAbbased ELISA binding ability. If thimerosal is used in bioprocessing procedures,free cysteine could be used later in the process for the regeneration of the critical cysteine residues,reversing some of the effects incurred due to the presence of thimerosal. In addition,alternative preservatives, such as 2-phenoxyethanol, which have been used in pneumococcal multi-dose vaccine formulations [37],should be considered for use in vaccine formulations when thimerosal is incompatible with the target antigens.

    5. Conclusions

    This study significantly advanced our understanding on the kinetics and nature of thiol-modifications by thimerosal, leading to partial or even complete loss of antigen function. Epitope-specific alterations in the antigenicity of HPV18 VLPs were characterized using a set of mAb-based immunochemical assays after thimerosal exposure. Deleterious effects of thiol-reactive thimerosal on the antigenicity and protein conformational stability of HPV18 VLPs were demonstrated in a thimerosal concentration-dependent manner with the time scale of antigen modifications defined. The kinetics of antigenicity loss due to thimerosal treatment was monitored with two different mAbs, showing distinctly different sets of kinetic parameters. Thiol modification may be the underlying event that results in the loss of antigenicity of HPV18 VLPs,coupled with structural alterations and substantially reduced protein stability.Efforts should be made in an in-depth understanding of the process and formulation with respect to the presence and maintenance of the clinically relevant epitopes on the vaccine antigen during vaccine bioprocessing, formulation and transportation.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    This work was funded by the National Natural Science Foundation of China (Grant Nos.: 81993149041, and U1705283), the National Science and Technology Major Project, China (Project No.:2018ZX09303005-002), Fujian Health Education Joint Research Project, China (Project No.: 2019-WJ-05) and Xiamen Science and Technology Major Project, China (Project No.: 3502Z20193009).We are grateful to Mr.Yibin Zhu,Mrs.Yue Zhang,Mr.Zhenqin Chen,Mr.Qingbing Zheng,and Mr.Yang Huang for their technical assistance.

    Appendix A. Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2020.08.007.

    亚洲精品视频女| 大片免费播放器 马上看| 在线 av 中文字幕| 亚洲国产看品久久| 高清黄色对白视频在线免费看| 人人妻人人澡人人看| 观看美女的网站| 久久久久国产精品人妻一区二区| 极品少妇高潮喷水抽搐| 久久女婷五月综合色啪小说| 日韩中字成人| 美女xxoo啪啪120秒动态图| www日本在线高清视频| 午夜精品国产一区二区电影| 久久精品人人爽人人爽视色| 亚洲av男天堂| 欧美 亚洲 国产 日韩一| 自线自在国产av| 老汉色av国产亚洲站长工具| 久久精品亚洲av国产电影网| 人人妻人人添人人爽欧美一区卜| 亚洲欧美日韩另类电影网站| 成年动漫av网址| 夫妻性生交免费视频一级片| 亚洲伊人久久精品综合| 亚洲精品国产av成人精品| 自线自在国产av| 国产成人精品福利久久| 性少妇av在线| 不卡av一区二区三区| 久久久国产欧美日韩av| 亚洲国产精品一区二区三区在线| 男女边吃奶边做爰视频| 国产日韩欧美视频二区| 久久精品国产亚洲av涩爱| av在线观看视频网站免费| 国产高清国产精品国产三级| 国产无遮挡羞羞视频在线观看| 宅男免费午夜| 香蕉国产在线看| 国产精品女同一区二区软件| 亚洲国产欧美日韩在线播放| 久久久久久久久久人人人人人人| 可以免费在线观看a视频的电影网站 | 免费av中文字幕在线| 久久国内精品自在自线图片| 国产精品香港三级国产av潘金莲 | videosex国产| 99久久中文字幕三级久久日本| 精品国产国语对白av| 青春草国产在线视频| 久久人人97超碰香蕉20202| 久久精品aⅴ一区二区三区四区 | 又大又黄又爽视频免费| 97在线视频观看| 综合色丁香网| 免费久久久久久久精品成人欧美视频| 久久热在线av| 色播在线永久视频| 人妻人人澡人人爽人人| 少妇熟女欧美另类| 国产精品久久久久久久久免| 精品亚洲乱码少妇综合久久| 精品一品国产午夜福利视频| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 18在线观看网站| 久久这里只有精品19| 18禁裸乳无遮挡动漫免费视频| 男女免费视频国产| 久久99蜜桃精品久久| 女人精品久久久久毛片| 在线观看美女被高潮喷水网站| 亚洲av免费高清在线观看| 久久久久久人人人人人| 秋霞伦理黄片| 国产男女超爽视频在线观看| 日韩av不卡免费在线播放| 亚洲国产av影院在线观看| 丰满迷人的少妇在线观看| 国产精品嫩草影院av在线观看| 久久久久久久大尺度免费视频| 日韩精品免费视频一区二区三区| 狠狠婷婷综合久久久久久88av| 黄片无遮挡物在线观看| 国产激情久久老熟女| 久久综合国产亚洲精品| 免费在线观看视频国产中文字幕亚洲 | 国产一级毛片在线| 久久久久国产网址| 最新中文字幕久久久久| 久久人人爽av亚洲精品天堂| 99久久综合免费| 少妇 在线观看| 男人添女人高潮全过程视频| 久久免费观看电影| 国产成人免费无遮挡视频| 韩国精品一区二区三区| 亚洲一码二码三码区别大吗| 国产精品免费大片| 精品国产超薄肉色丝袜足j| 欧美人与善性xxx| 欧美人与性动交α欧美精品济南到 | 少妇 在线观看| 巨乳人妻的诱惑在线观看| 亚洲,欧美,日韩| 国产免费福利视频在线观看| 日韩精品有码人妻一区| 国产高清国产精品国产三级| 日韩 亚洲 欧美在线| 亚洲图色成人| 69精品国产乱码久久久| 十分钟在线观看高清视频www| 国产综合精华液| 色婷婷久久久亚洲欧美| 18禁动态无遮挡网站| 亚洲少妇的诱惑av| 中文字幕人妻丝袜一区二区 | 1024视频免费在线观看| 亚洲一级一片aⅴ在线观看| 久久 成人 亚洲| 夜夜骑夜夜射夜夜干| 欧美 日韩 精品 国产| 亚洲国产毛片av蜜桃av| 日韩,欧美,国产一区二区三区| 国产成人精品无人区| 少妇人妻 视频| 成人18禁高潮啪啪吃奶动态图| 五月天丁香电影| 高清在线视频一区二区三区| 欧美+日韩+精品| 国产成人精品久久久久久| 如日韩欧美国产精品一区二区三区| 自拍欧美九色日韩亚洲蝌蚪91| 精品少妇久久久久久888优播| av不卡在线播放| 18禁观看日本| 熟女av电影| 日韩av不卡免费在线播放| 99久久中文字幕三级久久日本| 啦啦啦中文免费视频观看日本| 亚洲精品第二区| 精品一品国产午夜福利视频| 制服丝袜香蕉在线| 观看av在线不卡| 欧美另类一区| 老司机亚洲免费影院| 老熟女久久久| 成年人免费黄色播放视频| 亚洲精品视频女| 日韩av免费高清视频| 我要看黄色一级片免费的| 欧美日韩亚洲高清精品| 尾随美女入室| 亚洲av成人精品一二三区| 国产精品嫩草影院av在线观看| 蜜桃在线观看..| 最黄视频免费看| 美国免费a级毛片| 日韩欧美一区视频在线观看| 视频区图区小说| 一本大道久久a久久精品| 久久毛片免费看一区二区三区| 欧美日韩精品成人综合77777| 日本爱情动作片www.在线观看| 在线观看www视频免费| av国产久精品久网站免费入址| 亚洲情色 制服丝袜| 人妻少妇偷人精品九色| 亚洲国产精品成人久久小说| 久久精品久久精品一区二区三区| 精品少妇一区二区三区视频日本电影 | 亚洲av成人精品一二三区| 久久久久久久精品精品| 一级黄片播放器| 两个人免费观看高清视频| 亚洲av日韩在线播放| 99久久中文字幕三级久久日本| 丝袜美足系列| 自线自在国产av| www.av在线官网国产| 成人手机av| 午夜免费鲁丝| 少妇熟女欧美另类| 日韩一区二区视频免费看| 精品国产露脸久久av麻豆| 免费播放大片免费观看视频在线观看| 黄片播放在线免费| 精品少妇一区二区三区视频日本电影 | 久久青草综合色| 老汉色∧v一级毛片| 欧美黄色片欧美黄色片| 汤姆久久久久久久影院中文字幕| 国产亚洲欧美精品永久| 亚洲欧美清纯卡通| videos熟女内射| 免费大片黄手机在线观看| 免费观看a级毛片全部| 高清av免费在线| 国产视频首页在线观看| 在线 av 中文字幕| 一级黄片播放器| 欧美变态另类bdsm刘玥| 久久免费观看电影| 国产精品 欧美亚洲| 成年人午夜在线观看视频| 男人添女人高潮全过程视频| 国产成人精品久久久久久| 精品久久蜜臀av无| 中文字幕精品免费在线观看视频| 国产野战对白在线观看| 亚洲人成77777在线视频| 一区二区av电影网| 久久精品国产综合久久久| 久久久久久人妻| 国产精品.久久久| 又大又黄又爽视频免费| 午夜福利视频精品| 乱人伦中国视频| 亚洲成色77777| 极品人妻少妇av视频| 丝袜美足系列| 高清在线视频一区二区三区| 国产av码专区亚洲av| 色婷婷av一区二区三区视频| 日本爱情动作片www.在线观看| 久热久热在线精品观看| 黄色配什么色好看| 香蕉国产在线看| 亚洲精品久久午夜乱码| 久热久热在线精品观看| 成人黄色视频免费在线看| 国产一区亚洲一区在线观看| 中文字幕精品免费在线观看视频| 免费黄频网站在线观看国产| 国产有黄有色有爽视频| 日韩三级伦理在线观看| www日本在线高清视频| 亚洲国产看品久久| 久久免费观看电影| 中文字幕最新亚洲高清| 性色av一级| 91精品三级在线观看| 99香蕉大伊视频| 97在线视频观看| 人妻少妇偷人精品九色| 成年女人在线观看亚洲视频| 精品福利永久在线观看| 搡老乐熟女国产| 黄网站色视频无遮挡免费观看| 欧美人与善性xxx| 美女主播在线视频| 日日摸夜夜添夜夜爱| 99久久人妻综合| 午夜福利在线免费观看网站| 免费播放大片免费观看视频在线观看| 国产1区2区3区精品| 韩国精品一区二区三区| 叶爱在线成人免费视频播放| 成人国产av品久久久| 热re99久久精品国产66热6| 久久精品夜色国产| 日韩欧美一区视频在线观看| 久久99蜜桃精品久久| 国产免费视频播放在线视频| 久久久久久久大尺度免费视频| 国产一区二区激情短视频 | 国产淫语在线视频| 在线看a的网站| 欧美少妇被猛烈插入视频| 麻豆乱淫一区二区| a级片在线免费高清观看视频| 亚洲一区二区三区欧美精品| 精品一区在线观看国产| 亚洲精品在线美女| 成人免费观看视频高清| 成人国语在线视频| 五月天丁香电影| 亚洲视频免费观看视频| 午夜av观看不卡| 大片免费播放器 马上看| 国产野战对白在线观看| 天天操日日干夜夜撸| 亚洲精品国产色婷婷电影| 国产无遮挡羞羞视频在线观看| 国产在线视频一区二区| 菩萨蛮人人尽说江南好唐韦庄| 国产精品熟女久久久久浪| 少妇被粗大的猛进出69影院| 在线观看免费日韩欧美大片| 久久国产亚洲av麻豆专区| 亚洲图色成人| 国产男女超爽视频在线观看| 中文精品一卡2卡3卡4更新| 国产精品免费视频内射| 欧美老熟妇乱子伦牲交| 精品国产乱码久久久久久小说| 一级毛片我不卡| 国产淫语在线视频| 亚洲精品久久久久久婷婷小说| 亚洲 欧美一区二区三区| 老熟女久久久| 亚洲国产精品一区二区三区在线| 亚洲欧洲精品一区二区精品久久久 | 国产欧美日韩综合在线一区二区| 久久国产亚洲av麻豆专区| videos熟女内射| 人成视频在线观看免费观看| 国产高清国产精品国产三级| 久热久热在线精品观看| 国产男女超爽视频在线观看| 日韩大片免费观看网站| 一级毛片电影观看| 欧美成人午夜精品| 少妇被粗大的猛进出69影院| 国产免费福利视频在线观看| 有码 亚洲区| 亚洲精品中文字幕在线视频| 黑丝袜美女国产一区| 2018国产大陆天天弄谢| 99热全是精品| 五月开心婷婷网| 亚洲国产欧美在线一区| 一区二区三区激情视频| 性高湖久久久久久久久免费观看| 爱豆传媒免费全集在线观看| 99热全是精品| 久久女婷五月综合色啪小说| 97在线视频观看| 欧美成人精品欧美一级黄| 在线天堂中文资源库| 国产成人91sexporn| 最近2019中文字幕mv第一页| 久久精品国产亚洲av涩爱| 国产97色在线日韩免费| 久久久久国产精品人妻一区二区| 日本黄色日本黄色录像| 一本—道久久a久久精品蜜桃钙片| 亚洲精品第二区| 亚洲人成77777在线视频| 男女高潮啪啪啪动态图| 韩国精品一区二区三区| 日韩一本色道免费dvd| 啦啦啦视频在线资源免费观看| 欧美97在线视频| 哪个播放器可以免费观看大片| 天天躁日日躁夜夜躁夜夜| 热99久久久久精品小说推荐| 精品国产一区二区久久| 丝袜脚勾引网站| 久久久久精品人妻al黑| 精品午夜福利在线看| 国产精品久久久久久久久免| 国产av精品麻豆| 在线观看国产h片| 十八禁高潮呻吟视频| 免费高清在线观看视频在线观看| 亚洲国产欧美网| 少妇被粗大猛烈的视频| 亚洲成人手机| 久久久欧美国产精品| 亚洲欧美成人综合另类久久久| 下体分泌物呈黄色| 五月开心婷婷网| 免费av中文字幕在线| 老熟女久久久| 汤姆久久久久久久影院中文字幕| 丰满少妇做爰视频| a级片在线免费高清观看视频| 美女国产视频在线观看| 亚洲五月色婷婷综合| 久久国产精品大桥未久av| 两个人看的免费小视频| 91成人精品电影| 久久99精品国语久久久| 热99国产精品久久久久久7| 免费看不卡的av| 性少妇av在线| 久久久精品区二区三区| 亚洲欧美精品自产自拍| av国产精品久久久久影院| 日韩精品免费视频一区二区三区| 国产极品粉嫩免费观看在线| 午夜激情av网站| 夫妻性生交免费视频一级片| 成人18禁高潮啪啪吃奶动态图| 国产野战对白在线观看| 久久99蜜桃精品久久| 欧美国产精品va在线观看不卡| 蜜桃在线观看..| 一本—道久久a久久精品蜜桃钙片| 热re99久久精品国产66热6| 在线看a的网站| 毛片一级片免费看久久久久| 少妇被粗大的猛进出69影院| 亚洲av男天堂| 蜜桃国产av成人99| 电影成人av| av电影中文网址| 久久鲁丝午夜福利片| 欧美中文综合在线视频| 久久精品国产亚洲av天美| 1024视频免费在线观看| 亚洲欧美清纯卡通| www.av在线官网国产| 一级毛片电影观看| 丝袜喷水一区| 精品国产乱码久久久久久小说| 一二三四在线观看免费中文在| 国产精品一区二区在线观看99| 青春草亚洲视频在线观看| 日本91视频免费播放| 99香蕉大伊视频| 亚洲精品成人av观看孕妇| 免费观看在线日韩| 日日爽夜夜爽网站| 日韩在线高清观看一区二区三区| 中文字幕色久视频| 天天躁夜夜躁狠狠躁躁| 亚洲精品,欧美精品| 国产精品嫩草影院av在线观看| 久久久久久久久久久免费av| 中国国产av一级| 亚洲三级黄色毛片| 性少妇av在线| 日韩一区二区三区影片| 在线看a的网站| 午夜91福利影院| 亚洲久久久国产精品| 免费av中文字幕在线| 国产一区有黄有色的免费视频| 最新中文字幕久久久久| 韩国av在线不卡| 高清黄色对白视频在线免费看| 好男人视频免费观看在线| 91精品三级在线观看| 国产人伦9x9x在线观看 | 美女国产视频在线观看| 丝袜在线中文字幕| 这个男人来自地球电影免费观看 | 人妻系列 视频| 寂寞人妻少妇视频99o| 精品国产国语对白av| 亚洲国产日韩一区二区| 精品一区在线观看国产| videos熟女内射| 最黄视频免费看| 久久人人爽人人片av| 亚洲欧美精品自产自拍| 久久韩国三级中文字幕| 黄片小视频在线播放| av网站在线播放免费| 久久精品国产鲁丝片午夜精品| 国产精品无大码| 国产精品免费视频内射| 成年美女黄网站色视频大全免费| 毛片一级片免费看久久久久| 久久毛片免费看一区二区三区| 国产精品人妻久久久影院| 热re99久久精品国产66热6| 久久99一区二区三区| 久久午夜福利片| 91精品三级在线观看| 一级毛片电影观看| 午夜福利视频在线观看免费| 精品国产乱码久久久久久小说| 人妻系列 视频| 男的添女的下面高潮视频| 国产在视频线精品| 亚洲经典国产精华液单| 我的亚洲天堂| 国产午夜精品一二区理论片| 国产精品亚洲av一区麻豆 | av在线老鸭窝| 69精品国产乱码久久久| 天堂俺去俺来也www色官网| 大话2 男鬼变身卡| 色播在线永久视频| 岛国毛片在线播放| 亚洲情色 制服丝袜| 日韩精品免费视频一区二区三区| 中国三级夫妇交换| 乱人伦中国视频| 日本色播在线视频| 久久人人爽人人片av| 纵有疾风起免费观看全集完整版| 国语对白做爰xxxⅹ性视频网站| 黄色配什么色好看| 国产综合精华液| 久久av网站| 91久久精品国产一区二区三区| 精品一区二区三卡| 亚洲一级一片aⅴ在线观看| 丝瓜视频免费看黄片| 波多野结衣一区麻豆| 青春草国产在线视频| 亚洲av欧美aⅴ国产| 女性被躁到高潮视频| 亚洲国产精品一区二区三区在线| 人妻人人澡人人爽人人| 最近中文字幕2019免费版| 99久久综合免费| 色94色欧美一区二区| 在线观看免费高清a一片| 九草在线视频观看| 免费观看无遮挡的男女| 美女高潮到喷水免费观看| 啦啦啦视频在线资源免费观看| 久久久久国产网址| 国精品久久久久久国模美| 尾随美女入室| 成人18禁高潮啪啪吃奶动态图| 午夜福利乱码中文字幕| 中文字幕色久视频| 新久久久久国产一级毛片| 男人操女人黄网站| 蜜桃国产av成人99| 国产一区二区三区av在线| 99热全是精品| 2022亚洲国产成人精品| 欧美国产精品va在线观看不卡| 黑丝袜美女国产一区| 好男人视频免费观看在线| 亚洲成色77777| 丝袜美足系列| 欧美最新免费一区二区三区| 在线观看免费高清a一片| 国产精品.久久久| 卡戴珊不雅视频在线播放| 久久鲁丝午夜福利片| av在线播放精品| www.av在线官网国产| 黄色毛片三级朝国网站| 看免费成人av毛片| 亚洲精品av麻豆狂野| 捣出白浆h1v1| 国产av国产精品国产| 国产一区二区激情短视频 | 精品99又大又爽又粗少妇毛片| 中文字幕人妻熟女乱码| 男人舔女人的私密视频| 色婷婷av一区二区三区视频| 久久久a久久爽久久v久久| av又黄又爽大尺度在线免费看| 日韩电影二区| 久久久精品94久久精品| 国产精品不卡视频一区二区| 午夜免费鲁丝| 性高湖久久久久久久久免费观看| av国产久精品久网站免费入址| 中文字幕人妻丝袜制服| 亚洲一区中文字幕在线| 日韩av不卡免费在线播放| 国产精品国产三级国产专区5o| 日本av免费视频播放| 成年av动漫网址| 一本—道久久a久久精品蜜桃钙片| 国产免费又黄又爽又色| 欧美精品国产亚洲| h视频一区二区三区| 国产日韩一区二区三区精品不卡| 亚洲久久久国产精品| 亚洲,一卡二卡三卡| 国产男女超爽视频在线观看| 国语对白做爰xxxⅹ性视频网站| 满18在线观看网站| 亚洲精品第二区| 日本av免费视频播放| 自线自在国产av| 亚洲精品乱久久久久久| 久久久精品免费免费高清| 青春草亚洲视频在线观看| 欧美日本中文国产一区发布| 毛片一级片免费看久久久久| 精品国产乱码久久久久久男人| 免费日韩欧美在线观看| 中文天堂在线官网| 久久人人爽人人片av| 日韩中字成人| 99久久人妻综合| 大码成人一级视频| 少妇的逼水好多| 9色porny在线观看| 黄色配什么色好看| 午夜福利影视在线免费观看| 久久久久久久久久久久大奶| 国产亚洲一区二区精品| 26uuu在线亚洲综合色| 丝袜喷水一区| www.熟女人妻精品国产| 亚洲精品美女久久av网站| 久久精品国产综合久久久| 边亲边吃奶的免费视频| 久久精品久久久久久久性| 亚洲欧洲国产日韩| 亚洲国产毛片av蜜桃av| 伦理电影免费视频| 九草在线视频观看| 2021少妇久久久久久久久久久| 1024视频免费在线观看| 久久久久久人人人人人| 亚洲成国产人片在线观看| 赤兔流量卡办理| 亚洲色图综合在线观看| 日本免费在线观看一区| 少妇人妻精品综合一区二区| 欧美人与性动交α欧美精品济南到 | 男女无遮挡免费网站观看| 亚洲国产精品一区三区| 欧美激情极品国产一区二区三区| 人妻人人澡人人爽人人| 一级片免费观看大全| 黄色 视频免费看| 国产精品亚洲av一区麻豆 | 国产成人精品福利久久| 免费日韩欧美在线观看|